Invitae Reports More than 160% Annual Revenue Growth Driven by Nearly 140% Annual Growth in Volume in Second Quarter 2018
-- Raising annual revenue guidance amid strong quarter performance --
-- Q2 2018 gross profit of $16.9M up from $3.8M in Q2 2017 --
-- Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific --
SAN FRANCISCO, Aug. 7, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the second quarter ended June 30, 2018. Based on progress in the quarter, Invitae is raising its revenue guidance from more than $130 million to between $135 and $140 million in 2018.
"The combination of our broad and affordable diagnostic, reproductive health and proactive testing capabilities enables Invitae to answer genetic-related healthcare questions across all stages of life and opens up opportunity for growth as we bring genetics into mainstream medicine," said Sean George, co-founder and chief executive officer of Invitae. "Amidst the rapid growth in both volume and revenue, Invitae is emerging as a leader in the world of genetics. Given our progress, we're increasing our annual revenue guidance."
Second Quarter 2018 Results
- Accessioned more than 73,000 samples in the second quarter of 2018, a 14% sequential increase over the first quarter of 2018 and a 139% increase over the 30,500 samples in the second quarter of 2017.
- Generated revenue of $37.3 million in the second quarter of 2018, a 35% sequential increase over the first quarter of 2018 and a 161% increase over the second quarter of 2017 revenue of $14.3 million.
- Maintained the average cost per sample at $280 in the second quarter of 2018, flat from prior quarter, and a 19% reduction from a $345 average cost per sample in the second quarter of 2017.
- Achieved positive gross profit of $16.9 million in the second quarter of 2018 compared to a gross profit of $9.6 million in the first quarter of 2018, and $3.8 million gross profit in the second quarter of 2017.
Total operating expenses for the second quarter of 2018, excluding cost of goods sold, were $46.9 million compared to $31.9 million in the second quarter of 2017. For the second quarter of 2018, Invitae reported a net loss of $31.7 million, or a $0.47 loss per share, compared to a net loss of $28.6 million in the second quarter of 2017, or a $0.66 loss per share.
Cash used in operating activities for the quarter was $26.5 million, compared to $35.1 million in the first quarter of 2018. At June 30, 2018, cash, cash equivalents, restricted cash and marketable securities totaled $91.4 million which includes $53.5 million in net proceeds from an equity offering that closed in April. The company also has access to $20 million in additional debt, bringing total available capital at the quarter close to more than $110 million.
- Expanded the company's reproductive health offering with the launch of genetic carrier screening, a comprehensive test designed to provide affordable, accessible information on genetic changes that pose a risk for parents of having a child with an inherited genetic disorder
- Made significant progress on the integration and restructuring of the 2017 acquisitions, including the transfer of our Cambridge reproductive health technology to our San Francisco laboratory
- Continued growing our biopharma and patient advocacy network, launching seven biopharma partnership programs in the second quarter, including our SMA Identified program with Biogen to provide genetic testing to patients suspected of having or clinically diagnosed with SMA
- Began receiving payment from Medicare for deletion and duplication analysis (CPT code 81433)
- Published findings in the journal Genetics in Medicine from the largest analysis to date of genetic testing to identify deletions and duplications involving single genes using next-generation sequencing (NGS) techniques. The study found that these changes are present in a substantial number of patients and suggests that laboratory methods with high sensitivity to copy number variants (CNVs) should be a routine component of genetic testing
- Highlighted data at the American Society of Breast Surgeons (ASBS) showing that women who did not meet breast cancer genetic testing criteria had cancer-associated mutations just as often as women who met the criteria
- Presented findings at the American College of Medical Genetics (ACMG) annual meeting, indicating proactive genetic health screening reveals medically significant findings for a substantial portion of individuals tested, supporting the importance of proactive, clinical-grade testing in the absence of personal or family history of genetic disease.
Webcast and Conference Call Details
Management will host a conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss financial results and recent developments. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 3497996. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations.
The live webcast of the call may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website.
Invitae Corporation (NYSE: NVTA) is a genetics company whose mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time and lower prices.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's future financial performance and estimated guidance for 2018; the company's belief that its product mix opens up opportunities for growth; and that it is emerging as a leader in genetics. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.
Invitae Corporation Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) Three Months Ended Six Months Ended June 30, June 30, -------- -------- 2018 2017 2018 2017 ---- ---- ---- ---- (Unaudited) (Unaudited) Revenue: Test revenue $36,350 $13,592 $63,403 $23,287 Other revenue 956 744 1,574 1,387 --- --- ----- ----- Total revenue 37,306 14,336 64,977 24,674 Costs and operating expenses: Cost of test revenue 20,447 10,490 38,523 19,819 Research and development 15,784 11,339 31,150 21,362 Selling and marketing 18,707 12,520 37,631 24,092 General and administrative 12,436 8,062 24,216 14,813 ------ ----- ------ ------ Total costs and operating expenses 67,374 42,411 131,520 80,086 ------ ------ ------- ------ Loss from operations (30,068) (28,075) (66,543) (55,412) Other income (expense), net 188 151 1,835 (540) Interest expense (1,791) (1,067) (3,083) (1,389) ------ ------ ------ ------ Net loss before taxes (31,671) (28,991) (67,791) (57,341) Income tax benefit - (434) - (1,856) --- ---- --- ------ Net loss $(31,671) $(28,557) $(67,791) $(55,485) ======== ======== ======== ======== Net loss per share, basic and diluted $(0.47) $(0.66) $(1.12) $(1.30) Shares used in computing net loss per share, basic and diluted 67,806,606 43,226,569 60,775,077 42,808,175
Invitae Corporation Condensed Consolidated Balance Sheets (In thousands) June 30, December 31, 2018 2017 ---- ---- (Unaudited) Assets Current assets: Cash and cash equivalents $48,568 $12,053 Marketable securities 36,576 52,607 Accounts receivable 25,058 10,422 Prepaid expenses and other current assets 12,311 11,599 ------ ------ Total current assets 122,513 86,681 Property and equipment, net 28,816 30,341 Restricted cash 5,307 5,406 Marketable securities, non-current 900 5,983 Intangible assets, net 32,994 35,516 Goodwill 47,217 46,575 Other assets 1,329 576 ----- --- Total assets $239,076 $211,078 ======== ======== Liabilities and stockholders' equity Current liabilities: Accounts payable $5,200 $8,606 Accrued liabilities 22,566 22,742 Capital lease obligation, current portion 1,829 2,039 Debt, current portion 3,061 - ----- --- Total current liabilities 32,656 33,387 Capital lease obligation, net of current portion 2,413 3,373 Debt, net of current portion 55,575 39,084 Other long-term liabilities 9,785 13,440 ----- ------ Total liabilities 100,429 89,284 ------- ------ Stockholders' equity: Common stock 6 5 Accumulated other comprehensive loss (109) (171) Additional paid-in capital 593,898 520,558 Accumulated deficit (455,148) (398,598) -------- -------- Total stockholders' equity 138,647 121,794 ------- ------- Total liabilities and stockholders' equity $239,076 $211,078 ======== ========
The condensed, consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated financial statements at that date included in the company's Annual Report on Form 10-K for the year ended December 31, 2017.
View original content with multimedia:http://www.prnewswire.com/news-releases/invitae-reports-more-than-160-annual-revenue-growth-driven-by-nearly-140-annual-growth-in-volume-in-second-quarter-2018-300693488.html
SOURCE Invitae Corporation
Company Codes: NYSE:NVTA